Home › Islet Cell Adenoma › Massachusetts
Islet Cell Adenoma clinical trials in Massachusetts
3 studies for Islet Cell Adenoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Massachusetts General Hospital ( Site 0111), Boston
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Nov 13, 2026 · NCT04924075Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06943755A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06881992From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.